María Basagaña

4CPS-292 Plasma omalizumab levels and fcεRI expression: tools for optimising asthma therapy

M E Navarrete Rouco, Ramón Gimeno, A Garcia, Mireia Admetlló et autres

Background and Importance Omalizumab is approved for chronic use; however, in patients with clinical remission, dose reduction may be feasible. Plasma omalizumab concentration and FcεRI receptor levels, related to free IgE, may help guide dosing optimisation. Aim and Objectives We aimed to …

es (code pays fourni par la source)

Comorbidities as a Personalized Target in Patients with Severe Asthma Treated with Dupilumab

Carlota Gonzalez-Lluch, María Basagaña, Laura Pardo, Paula Toro et autres

Background: This study aimed to evaluate the clinical effectiveness of dupilumab and its impact on CRSwNP and type 2 inflammatory biomarkers in patients with severe uncontrolled asthma, with or without comorbidities, within a real-life cohort. Methods: This was a single-center, prospective, and …

es (code pays fourni par la source)

Presence of nanoplastics in sputum of patients with severe asthma: a novel environmental perspective

Leandro Tapia Barredo, Agnes Hernandez Biette, Paula Gonçalves Romeu, Raquel Guillamat Prats et autres

Studies suggest that environmental exposure to micro-and-nanoplastics (MNPs) may influence asthma pathophysiology given their potential to trigger and maintain immune responses. Evidence is lacking regarding the link between the presence of MNPs and disease severity and phenotypes. We aim to understand their …

es (code pays fourni par la source)

Real-world Impact of Tezepelumab in Severe Asthma: insights from the ADVANCAT Study (Advancing Severe Asthma Care with Tezepelumab in Catalonia)

Ebymar Arismendi, María Basagaña, Astrid Crespo, Olga Luengo et autres

Introduction: Tezepelumab, a monoclonal antibody targeting TSLP, has shown efficacy in reducing exacerbations and improving severe asthma control. This multicenter registry evaluates its real-world effectiveness. Objective: To assess effectiveness of tezepelumab in uncontrolled severe asthma using clinical, functional and innovative parameters. Methods: …

es (code pays fourni par la source)

RESULTADOS PRELIMINARES SOBRE LA EFECTIVIDAD DE LA OPTIMIZACIÓN TERAPÉUTICA DEL OMALIZUMAB EN PACIENTES ASMATICOS: ENSAYO CLÍNICO FASE IV

María Eugenia Navarrete-Rouco, Angela Garcia Sanz, Mireia Admetlló Papiol, María Basagaña et autres

17 al 19 de Octubre del 2024. 70 Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria(SEFH). Participa en el evento científico por excelencia en el marco de la Farmacia Hospitalaria en España.

Prognostic Factors in Severe Eosinophilic Asthma in a Pediatric Population: A Prospective Cohort Study in Spain

Clara Padró-Casas, María Basagaña, María del Mar Martínez-Colls, Ignasi García-Olivé et autres

Background/Objectives: The objective of this study was to provide real-world data on prognostic factors in children with severe eosinophilic asthma and to assess biomarkers of outcome. Methods: Fifty-nine children (aged 6–17 years) were included in a prospective cohort attended in a Severe …

es (code pays fourni par la source)

Identification and tracking of patients with uncontrolled severe asthma in the Germans Trias i Pujol Hospital Health Area

Anna Núñez, Toni Zapata, Ignasi García Olivé, Alan Junior Solis et autres

Introduction: Patients with severe asthma should be managed in an Asthma Unit (AU) or by a pulmonologist in the area, especially if they've needed emergency care for exacerbation. The COVID-19 pandemic has likely disrupted their access to healthcare. We aimed to assess …

es (code pays fourni par la source)

Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients

Cristina Esquinas López, Nathalie Depreux, Isabel Roca Bielsa, Albert Roger et autres

Background: Chronic spontaneous urticaria (CSU) is a highly prevalent and difficult to manage cutaneous disease characterized by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. One of the biological treatments used for patients with …

es (code pays fourni par la source)

Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis

María Basagaña, Carlos Martínez‐Rivera, Clara Padró, Ignasi García-Olivé et autres

Background Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients’ characteristics are different from those encountered in asthma patients in the real-world setting. The aim of …

es (code pays fourni par la source)

Efficacy of benralizumab and mepolizumab in treating severe eosinophilic asthma: A one-year study on clinical remission and response

Anna Núñez, María Basagaña, Toni Zapata, Alan Junior Solis et autres

Background: It is important to add scientific evidence with real-life data on the effect of different biologics directed against the IL-5 pathway. Aims and objectives: To confirm the effect on clinical remission (CR) and identify factors associated with good response. Methods: Retrospective …

es (code pays fourni par la source)

Characterization and Factors Associated with Poor Asthma Control in Adults with Severe Eosinophilic Asthma

Clara Padró-Casas, María Basagaña, María Rivera-Ortún, Ignasi García-Olivé et autres

A study was conducted in 98 adult patients diagnosed with severe eosinophilic asthma (73.5% women, mean age 47.2 years) and followed prospectively for 1 year. The aim of the study was to characterize this population and to identify factors associated with poor …

es (code pays fourni par la source)

Peripheral blood T cell modulation by omalizumab in chronic urticaria patients

Cristina Esquinas López, Nathalie Depreux, Isabel Bielsa, Albert Roger et autres

Abstract Background: Chronic spontaneous urticaria (CSU) is a highly prevalent and difficult to manage disease. One of the main treatments used in CSU is the monoclonal antibody omalizumab, which effect on the immune system is still unknown. The understanding of the mechanism …

es (code pays fourni par la source)